In this competitive revision proposal we seek to pursue as a new and additional specific aim the development of practical synthetic routes to the cortistatin family of alkaloids, broadly defined. Our approach is based on a versatile advanced synthetic template from which a diverse array of natural and unnatural cortistatins can be rapidly prepared. Analogs widely variant in the A and D rings, as well as along the skeleton connecting these rings will be prepared. We plan to evaluate the effects of the compounds we prepare upon the growth of HUVECs and thereby to develop a comprehensive profile of structure-activity relationships within the class. We also plan to synthesize molecular probes as tools for the identification of protein target(s) of the cortistatins. We propose to synthesize key intermediates for the production of cortistatins in multi-gram amounts from which we will pursue the preparation of large numbers of cortistatin analogs that otherwise would be inaccessible. This proposal is a competitive revision application. Notice Number: NOT-OD-09-058 n Notice Title: NIH Announces the Availability of Recovery Act Funds for Competitive Revisions Applications

Public Health Relevance

Angiogenesis is the process of new blood vessel growth from existing vasculature, and unregulated angiogenesis has been implicated in a variety of diseases including atherosclerosis, macular degeneration, and many forms of cancer. The development of small-molecule inhibitors of angiogenesis provides one of the most promising avenues of therapy for patients with these illnesses. The overall goal of this project is to develop a means to synthesize in the laboratory analogs of the extremely potent natural angiogenesis inhibitors known as the cortistatins, which may serve as lead structures in pharmaceutical design, as well as biological probes to elucidate the protein target(s) of these compounds in vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA047148-22S1
Application #
7811820
Study Section
Special Emphasis Panel (ZRG1-BCMB-H (95))
Program Officer
Lees, Robert G
Project Start
1988-04-01
Project End
2011-01-31
Budget Start
2009-09-30
Budget End
2011-01-31
Support Year
22
Fiscal Year
2009
Total Cost
$344,260
Indirect Cost
Name
Harvard University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
082359691
City
Cambridge
State
MA
Country
United States
Zip Code
02138
Mortison, Jonathan D; Schenone, Monica; Myers, Jacob A et al. (2018) Tetracyclines Modify Translation by Targeting Key Human rRNA Substructures. Cell Chem Biol 25:1506-1518.e13
Andresen, Vibeke; Erikstein, Bjarte S; Mukherjee, Herschel et al. (2016) Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death Dis 7:e2497
Mukherjee, Herschel; Chan, Kok-Ping; Andresen, Vibeke et al. (2015) Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants. ACS Chem Biol 10:855-63
Blasdel, Landy K; Lee, DongEun; Sun, Binyuan et al. (2013) (S)-4-Trimethylsilyl-3-butyn-2-ol as an auxiliary for stereocontrolled synthesis of salinosporamide analogs with modifications at positions C2 and C5. Bioorg Med Chem Lett 23:6905-10
Magauer, Thomas; Smaltz, Daniel J; Myers, Andrew G (2013) Component-based syntheses of trioxacarcin A, DC-45-A1 and structural analogues. Nat Chem 5:886-93
Hugelshofer, Cedric L; Mellem, Kevin T; Myers, Andrew G (2013) Synthesis of quaternary ?-methyl ?-amino acids by asymmetric alkylation of pseudoephenamine alaninamide pivaldimine. Org Lett 15:3134-7
Mellem, Kevin T; Myers, Andrew G (2013) A simple, scalable synthetic route to (+)- and (-)-pseudoephenamine. Org Lett 15:5594-7
Morales, Marvin R; Mellem, Kevin T; Myers, Andrew G (2012) Pseudoephenamine: a practical chiral auxiliary for asymmetric synthesis. Angew Chem Int Ed Engl 51:4568-71
Smaltz, Daniel J; Švenda, Jakub; Myers, Andrew G (2012) Diastereoselective additions of allylmetal reagents to free and protected syn-?,?-dihydroxyketones enable efficient synthetic routes to methyl trioxacarcinoside A. Org Lett 14:1812-5
Svenda, Jakub; Hill, Nicholas; Myers, Andrew G (2011) A multiply convergent platform for the synthesis of trioxacarcins. Proc Natl Acad Sci U S A 108:6709-14

Showing the most recent 10 out of 19 publications